MUMBAI (Thomson Financial) - India's Lupin Ltd. said its U.S. subsidiary Lupin Pharmaceutical Inc. (LPI) has received tentative abbreviated new drug application approval from the U.S. Food and Drug Administration for its Escitalopram Oxalate tablets in strengths of 10 mg and 20 mg.
Lupin's Escitalopram tablets are the AB rated generic equivalent of Lexapro tablets, indicated for the treatment of major depressive disorder.
The product will be introduced in the market through LPI's network of national wholesalers and drug stores, post patent expiry in March 2012, the company said.
At 12:51 pm, the company's shares were 2.56 percent up at 722.00 rupees, while the benchmark Sensex was 1.94 percent higher at 15,484.46.
tfn.newsdesk@thomson.com arc/ypv/slm COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
Lupin's Escitalopram tablets are the AB rated generic equivalent of Lexapro tablets, indicated for the treatment of major depressive disorder.
The product will be introduced in the market through LPI's network of national wholesalers and drug stores, post patent expiry in March 2012, the company said.
At 12:51 pm, the company's shares were 2.56 percent up at 722.00 rupees, while the benchmark Sensex was 1.94 percent higher at 15,484.46.
tfn.newsdesk@thomson.com arc/ypv/slm COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2008 AFX News
